share_log

Aditxt | 8-K/A: Current report (Amendment)

Aditxt | 8-K/A: Current report (Amendment)

Aditxt | 8-K/A：重大事件(修正)
美股SEC公告 ·  2024/09/05 06:22

Moomoo AI 已提取核心訊息

Aditxt Inc. has filed pro forma consolidated financial statements reflecting its acquisitions of Evofem Biosciences and Appili Therapeutics. The pro forma statements show combined assets of $168.5 million and total liabilities of $63.7 million as of June 30, 2024.The transactions include Aditxt's acquisition of Appili through its subsidiary Adivir, where Appili shareholders will receive 0.002745004 Aditxt shares and $0.0467 in cash per Appili share. For Evofem, the consideration includes $91.6 million in convertible preferred stock, $1.8 million cash payment to stockholders, and assumption of $13 million in senior secured notes.The pro forma consolidated statement shows a net loss of $30.2 million for the six months ended June 30, 2024. The preliminary purchase price allocation resulted in goodwill of $134.8 million and intangible assets of $6.3 million. Management notes these pro forma statements are preliminary and subject to refinement as additional fair value information becomes available within one year of closing.
Aditxt Inc. has filed pro forma consolidated financial statements reflecting its acquisitions of Evofem Biosciences and Appili Therapeutics. The pro forma statements show combined assets of $168.5 million and total liabilities of $63.7 million as of June 30, 2024.The transactions include Aditxt's acquisition of Appili through its subsidiary Adivir, where Appili shareholders will receive 0.002745004 Aditxt shares and $0.0467 in cash per Appili share. For Evofem, the consideration includes $91.6 million in convertible preferred stock, $1.8 million cash payment to stockholders, and assumption of $13 million in senior secured notes.The pro forma consolidated statement shows a net loss of $30.2 million for the six months ended June 30, 2024. The preliminary purchase price allocation resulted in goodwill of $134.8 million and intangible assets of $6.3 million. Management notes these pro forma statements are preliminary and subject to refinement as additional fair value information becomes available within one year of closing.
Aditxt公司已提交了包含Evofem Biosciences和Appili Therapeutics收購的臨時合併基本報表。這些臨時報表顯示，截至2024年6月30日，合併資產爲16850萬美元，總負債爲6370萬美元。交易包括Aditxt通過其子公司Adivir收購Appili，Appili的股東將獲得每股Appili 0.002745004股Aditxt股份和0.0467美元現金。對於Evofem，交易包括9160萬美元的可轉換優先股、180萬美元的現金支付給股東，以及承擔1300萬美元的高級擔保票據。臨時合併報表顯示截至2024年6月30日的六個月內淨損失爲3020萬美元。初步購買價格分配導致商譽爲13480萬美元，無形資產爲630萬美元。管理層指出，這些臨時報表爲初步數據，並需根據在關閉一年內獲得的附加公允價值信息進行修訂。
Aditxt公司已提交了包含Evofem Biosciences和Appili Therapeutics收購的臨時合併基本報表。這些臨時報表顯示，截至2024年6月30日，合併資產爲16850萬美元，總負債爲6370萬美元。交易包括Aditxt通過其子公司Adivir收購Appili，Appili的股東將獲得每股Appili 0.002745004股Aditxt股份和0.0467美元現金。對於Evofem，交易包括9160萬美元的可轉換優先股、180萬美元的現金支付給股東，以及承擔1300萬美元的高級擔保票據。臨時合併報表顯示截至2024年6月30日的六個月內淨損失爲3020萬美元。初步購買價格分配導致商譽爲13480萬美元，無形資產爲630萬美元。管理層指出，這些臨時報表爲初步數據，並需根據在關閉一年內獲得的附加公允價值信息進行修訂。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    OSR Holdings
    OSRH
    -- 3.790
    Ocean Biomedical
    OCEA
    -- 0.084
    Alumis
    ALMS
    -- 4.920
    Theratechnologies
    THTX
    -- 1.8600
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.4000
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    中概股財報季火熱：驚喜盈利能否延續漲勢？
    1. 哪些行業可能成為本輪財報季的市場焦點？ 2. 在政府強調科技創新和可持續發展的背景下，你認為哪些行業具有最大的增長潜力？ 展开
    中國兩會：會議前後股票價格變動的關鍵要點